$arna APD371 Not a Big Deal. Testing limited to crohn's stomach pain. Many exclusions on subjects. Trouble recruiting. N=20. Long hx of cb2 fails.
#pharma#stocks#biotechworld#oprah#drphil $AGN $nktr
$arna Unlike all the previous dilutions the 7 underwriters for this most recent one are able to short immediately. In past underwriters needed to wait.
Does $arna mgmt really standstill as peeps afflilated with a music blog and other retail to send letters with outrageous pumps, pr promotions to WS analysts, funds, BP? LOL
WF compares $arna Etrasimod to Fingolimod. Wonder if they compared it to the Fingolimod ANDA's from $Teva, #Aurobindopharma, Zydus, Torrent, Biocon, Strides, Prinston, MSN Labs PVT LTD, Alembic, all FDA approved in 2017.
#pharma#biotech#generic#Biotechnology#stock#stocks
$arna expecting -140.19% YoY EPS growth, -94.81% YoY revenue growth, weak PAH data, UC drug has admitted patent issues, pipe years from FDA, only drug has 2 patent challenges. Yes. Worthy of upgrade. #stocks#biotech#pharma
$arna has divulged patent issues may effect commercialization of delayed Etrasimod. Many trials left for this 14year old research compound #stocks#pharma#biotech#Biotechnology
I wish $arna was a #Marijuana stock. Alas, it isn't. Only has a dud diet pill w/chronic low revenues. Had 3 dilutions and RS in 2017. Settled Class Action suit $EMHTF $ACBFF $PRMCF $APHQF $TWMJF $CARA $GWPH $XNET $ZYNE $VFFIF
After listening to $arna CEO at their conferences JPM doesn't place $arna on it's 2018 buyside M & A candidate list that has 35 potential Bio targets. #stocks#biotech#pharma#oprah#drphil
$arna Gets $12 Million for both ralinepag and etrasimod from unknown Everest Medicines recently started by Chinese fund C-bridge other details of deal for 5 territories lack specifics.